FDA warns against co-administration of remdesivir with CQ or HCQ for COVID-19 patients

"FDA is warning health care providers that co-administration of remdesivir and chloroquine phosphate or hydroxychloroquine sulfate is not recommended as it may result in reduced antiviral activity of remdesivir. The agency is not aware of instances of this reduced activity occurring in the clinical setting but is continuing to evaluate all data related to remdesivir," the FDA said in a statement.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/3d5HsIf
via IFTTT